



## Spinal Muscular Atrophy Medicine Industry Research Report 2026

Industry	Published	Pages	Format
Pharma & Healthcare	2025-12-26	131	PDF

Single User	Multi User	Enterprise
USD 2,950	USD 4,430	USD 5,900

### Description

The global Spinal Muscular Atrophy Medicine market was valued at US\$ million in 2025 and is projected to reach US\$ million by 2032, implying a CAGR of % over 2026–2032.

The North America market for Spinal Muscular Atrophy Medicine is projected to increase from US\$ million in 2026 to US\$ million by 2032, corresponding to a CAGR of % over 2026–2032.

The Europe market for Spinal Muscular Atrophy Medicine is projected to rise from US\$ million in 2026 to US\$ million by 2032, registering a CAGR of % over 2026–2032.

The Asia Pacific market for Spinal Muscular Atrophy Medicine is expected to grow from US\$ million in 2026 to US\$ million by 2032, at a CAGR of % over 2026–2032.

Leading global manufacturers of Spinal Muscular Atrophy Medicine include Novartis AG, Astellas Pharma Inc., WAVE Life Sciences Ltd., Vybion, Inc., Voyager Therapeutics, Inc., Sarepta Therapeutics, Inc., Neurotune AG, Neurodyn Inc. and Longevity Biotech, Inc, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

### Report Scope

This report quantifies the global Spinal Muscular Atrophy Medicine market in terms of revenue (US\$ million) and, where applicable, sales volume (W Units), using 2025 as the base year and providing annual historical and forecast data for 2021–2032.

It standardizes definitions of Types and Applications, harmonizes vendor attribution, and presents comparable time series by company, Type, Application, and region/country, including indicative price bands (US\$/W Units) and concentration ratios (CR5/CR10).

The outputs are intended to support strategy development, budgeting, and performance benchmarking for brand owners, manufacturers, retailers, channel partners, and investors; data are structured with consistent units and fields to facilitate integration into internal FP&A and BI systems.

### Key Companies & Market Share Insights

This section profiles leading manufacturers, combining 2021–2025 results with a 2026–2032 outlook. It reports revenue, market share, price bands, product and application mix, regional and channel mix, and key developments (M&A, capacity additions, certifications). It also provides global revenue, average price, and—where applicable—sales volume by manufacturer, and calculates CR5/CR10 and rank changes to support comparative benchmarking.

Spinal Muscular Atrophy Medicine Market by Company

Novartis AG

Astellas Pharma Inc.

WAVE Life Sciences Ltd.  
Vybion, Inc.  
Voyager Therapeutics, Inc.  
Sarepta Therapeutics, Inc.  
Neurotune AG  
Neurodyn Inc.  
Longevity Biotech, Inc  
Ionis Pharmaceuticals, Inc.  
GMP-Orphan SAS  
Genzyme Corporation  
Genethon  
F. Hoffmann-La Roche Ltd.  
Cytokinetics, Inc. 24  
Bioblast Pharma Ltd.  
AveXis, Inc.

### **Spinal Muscular Atrophy Medicine Segment by Type**

LMI-070  
ND-602  
NT-1654  
NXD-30001  
Nusinersen  
Others

### **Spinal Muscular Atrophy Medicine Segment by Application**

Hospital  
Clinic  
Others

### **Spinal Muscular Atrophy Medicine Segment by Region**

North America  
United States  
Canada  
Europe  
Germany  
France  
U.K.  
Italy  
Russia  
Spain  
Netherlands  
Switzerland  
Sweden  
Poland  
Asia-Pacific  
China  
Japan  
South Korea  
India

Australia  
Taiwan  
Southeast Asia  
South America  
Brazil  
Argentina  
Chile  
Middle East & Africa  
Egypt  
South Africa  
Israel  
Türkiye  
GCC Countries

## **Key Drivers & Barriers**

High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.

## **Reasons to Buy This Report**

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Spinal Muscular Atrophy Medicine market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Spinal Muscular Atrophy Medicine and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Spinal Muscular Atrophy Medicine.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

## **Chapter Outline**

### **Chapter 1:**

Research objectives, research methods, data sources, data cross-validation;

### **Chapter 2:**

Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

**Chapter 3:**

Detailed analysis of Spinal Muscular Atrophy Medicine manufacturers competitive landscape, price, production and value market share, latest development plan, merger, and acquisition information, etc.

**Chapter 4:**

Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product production/output, value, price, gross margin, product introduction, recent development, etc.

**Chapter 5:**

Production/output, value of Spinal Muscular Atrophy Medicine by region/country. It provides a quantitative analysis of the market size and development potential of each region in the next six years.

**Chapter 6:**

Consumption of Spinal Muscular Atrophy Medicine in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and production of each country in the world.

**Chapter 7:**

Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

**Chapter 8:**

Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

**Chapter 9:**

Analysis of industrial chain, including the upstream and downstream of the industry.

**Chapter 10:**

Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

**Chapter 11:**

The main points and conclusions of the report.

# Table of Contents

---

## 1 Preface

- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
  - 1.5.1 Secondary Sources
  - 1.5.2 Primary Sources

---

## 2 Market Overview

- 2.1 Product Definition
- 2.2 Global Market Growth Prospects
  - 2.2.1 Global Spinal Muscular Atrophy Medicine Market Size (2021-2032)
  - 2.2.2 Global Spinal Muscular Atrophy Medicine Sales (2021-2032)
  - 2.2.3 Global Spinal Muscular Atrophy Medicine Market Average Price (2021-2032)
- 2.3 Spinal Muscular Atrophy Medicine by Type
  - 2.3.1 Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US\$ Million)
  - 2.3.2 LMI-070
  - 2.3.3 ND-602
  - 2.3.4 NT-1654
  - 2.3.5 NXD-30001
  - 2.3.6 Nusinersen
  - 2.3.7 Others
- 2.4 Spinal Muscular Atrophy Medicine by Application
  - 2.4.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
  - 2.4.2 Hospital
  - 2.4.3 Clinic
  - 2.4.4 Others

---

## 3 Market Competitive Landscape by Manufacturers

- 3.1 Global Spinal Muscular Atrophy Medicine Market Competitive Situation by Manufacturers (2021 Versus 2025)
- 3.2 Global Spinal Muscular Atrophy Medicine Sales (W Units) of Manufacturers (2021-2026)
- 3.3 Global Spinal Muscular Atrophy Medicine Revenue of Manufacturers (2021-2026)
- 3.4 Global Spinal Muscular Atrophy Medicine Average Price by Manufacturers (2021-2026)
- 3.5 Global Spinal Muscular Atrophy Medicine Industry Ranking, 2024 VS 2025 VS 2026
- 3.6 Global Manufacturers of Spinal Muscular Atrophy Medicine, Manufacturing Sites & Headquarters
- 3.7 Global Manufacturers of Spinal Muscular Atrophy Medicine, Product Type & Application
- 3.8 Global Manufacturers of Spinal Muscular Atrophy Medicine, Established Date
- 3.9 Global Spinal Muscular Atrophy Medicine Market CR5 and HHI
- 3.10 Global Manufacturers Mergers & Acquisition

---

## 4 Manufacturers Profiled

- 4.1 Novartis AG
  - 4.1.1 Novartis AG Company Information
  - 4.1.2 Novartis AG Business Overview
  - 4.1.3 Novartis AG Spinal Muscular Atrophy Medicine Sales, Revenue and Gross Margin (2021-2026)

- 4.1.4 Novartis AG Spinal Muscular Atrophy Medicine Product Portfolio
- 4.1.5 Novartis AG Recent Developments
- 4.2 Astellas Pharma Inc.
  - 4.2.1 Astellas Pharma Inc. Company Information
  - 4.2.2 Astellas Pharma Inc. Business Overview
  - 4.2.3 Astellas Pharma Inc. Spinal Muscular Atrophy Medicine Sales, Revenue and Gross Margin (2021-2026)
  - 4.2.4 Astellas Pharma Inc. Spinal Muscular Atrophy Medicine Product Portfolio
  - 4.2.5 Astellas Pharma Inc. Recent Developments
- 4.3 WAVE Life Sciences Ltd.
  - 4.3.1 WAVE Life Sciences Ltd. Company Information
  - 4.3.2 WAVE Life Sciences Ltd. Business Overview
  - 4.3.3 WAVE Life Sciences Ltd. Spinal Muscular Atrophy Medicine Sales, Revenue and Gross Margin (2021-2026)
  - 4.3.4 WAVE Life Sciences Ltd. Spinal Muscular Atrophy Medicine Product Portfolio
  - 4.3.5 WAVE Life Sciences Ltd. Recent Developments
- 4.4 Vybion, Inc.
  - 4.4.1 Vybion, Inc. Company Information
  - 4.4.2 Vybion, Inc. Business Overview
  - 4.4.3 Vybion, Inc. Spinal Muscular Atrophy Medicine Sales, Revenue and Gross Margin (2021-2026)
  - 4.4.4 Vybion, Inc. Spinal Muscular Atrophy Medicine Product Portfolio
  - 4.4.5 Vybion, Inc. Recent Developments
- 4.5 Voyager Therapeutics, Inc.
  - 4.5.1 Voyager Therapeutics, Inc. Company Information
  - 4.5.2 Voyager Therapeutics, Inc. Business Overview
  - 4.5.3 Voyager Therapeutics, Inc. Spinal Muscular Atrophy Medicine Sales, Revenue and Gross Margin (2021-2026)
  - 4.5.4 Voyager Therapeutics, Inc. Spinal Muscular Atrophy Medicine Product Portfolio
  - 4.5.5 Voyager Therapeutics, Inc. Recent Developments
- 4.6 Sarepta Therapeutics, Inc.
  - 4.6.1 Sarepta Therapeutics, Inc. Company Information
  - 4.6.2 Sarepta Therapeutics, Inc. Business Overview
  - 4.6.3 Sarepta Therapeutics, Inc. Spinal Muscular Atrophy Medicine Sales, Revenue and Gross Margin (2021-2026)
  - 4.6.4 Sarepta Therapeutics, Inc. Spinal Muscular Atrophy Medicine Product Portfolio
  - 4.6.5 Sarepta Therapeutics, Inc. Recent Developments
- 4.7 Neurotune AG
  - 4.7.1 Neurotune AG Company Information
  - 4.7.2 Neurotune AG Business Overview
  - 4.7.3 Neurotune AG Spinal Muscular Atrophy Medicine Sales, Revenue and Gross Margin (2021-2026)
  - 4.7.4 Neurotune AG Spinal Muscular Atrophy Medicine Product Portfolio
  - 4.7.5 Neurotune AG Recent Developments
- 4.8 Neurodyn Inc.
  - 4.8.1 Neurodyn Inc. Company Information
  - 4.8.2 Neurodyn Inc. Business Overview
  - 4.8.3 Neurodyn Inc. Spinal Muscular Atrophy Medicine Sales, Revenue and Gross Margin (2021-2026)
  - 4.8.4 Neurodyn Inc. Spinal Muscular Atrophy Medicine Product Portfolio
  - 4.8.5 Neurodyn Inc. Recent Developments
- 4.9 Longevity Biotech, Inc.
  - 4.9.1 Longevity Biotech, Inc Company Information
  - 4.9.2 Longevity Biotech, Inc Business Overview
  - 4.9.3 Longevity Biotech, Inc Spinal Muscular Atrophy Medicine Sales, Revenue and Gross Margin (2021-2026)

- 4.9.4 Longevity Biotech, Inc Spinal Muscular Atrophy Medicine Product Portfolio
- 4.9.5 Longevity Biotech, Inc Recent Developments
- 4.10 Ionis Pharmaceuticals, Inc.
  - 4.10.1 Ionis Pharmaceuticals, Inc. Company Information
  - 4.10.2 Ionis Pharmaceuticals, Inc. Business Overview
  - 4.10.3 Ionis Pharmaceuticals, Inc. Spinal Muscular Atrophy Medicine Sales, Revenue and Gross Margin (2021-2026)
  - 4.10.4 Ionis Pharmaceuticals, Inc. Spinal Muscular Atrophy Medicine Product Portfolio
  - 4.10.5 Ionis Pharmaceuticals, Inc. Recent Developments
- 4.11 GMP-Orphan SAS
  - 4.11.1 GMP-Orphan SAS Company Information
  - 4.11.2 GMP-Orphan SAS Business Overview
  - 4.11.3 GMP-Orphan SAS Spinal Muscular Atrophy Medicine Sales, Revenue and Gross Margin (2021-2026)
  - 4.11.4 GMP-Orphan SAS Spinal Muscular Atrophy Medicine Product Portfolio
  - 4.11.5 GMP-Orphan SAS Recent Developments
- 4.12 Genzyme Corporation
  - 4.12.1 Genzyme Corporation Company Information
  - 4.12.2 Genzyme Corporation Business Overview
  - 4.12.3 Genzyme Corporation Spinal Muscular Atrophy Medicine Sales, Revenue and Gross Margin (2021-2026)
  - 4.12.4 Genzyme Corporation Spinal Muscular Atrophy Medicine Product Portfolio
  - 4.12.5 Genzyme Corporation Recent Developments
- 4.13 Genethon
  - 4.13.1 Genethon Company Information
  - 4.13.2 Genethon Business Overview
  - 4.13.3 Genethon Spinal Muscular Atrophy Medicine Sales, Revenue and Gross Margin (2021-2026)
  - 4.13.4 Genethon Spinal Muscular Atrophy Medicine Product Portfolio
  - 4.13.5 Genethon Recent Developments
- 4.14 F. Hoffmann-La Roche Ltd.
  - 4.14.1 F. Hoffmann-La Roche Ltd. Company Information
  - 4.14.2 F. Hoffmann-La Roche Ltd. Business Overview
  - 4.14.3 F. Hoffmann-La Roche Ltd. Spinal Muscular Atrophy Medicine Sales, Revenue and Gross Margin (2021-2026)
  - 4.14.4 F. Hoffmann-La Roche Ltd. Spinal Muscular Atrophy Medicine Product Portfolio
  - 4.14.5 F. Hoffmann-La Roche Ltd. Recent Developments
- 4.15 Cytokinetics, Inc. 24
  - 4.15.1 Cytokinetics, Inc. 24 Company Information
  - 4.15.2 Cytokinetics, Inc. 24 Business Overview
  - 4.15.3 Cytokinetics, Inc. 24 Spinal Muscular Atrophy Medicine Sales, Revenue and Gross Margin (2021-2026)
  - 4.15.4 Cytokinetics, Inc. 24 Spinal Muscular Atrophy Medicine Product Portfolio
  - 4.15.5 Cytokinetics, Inc. 24 Recent Developments
- 4.16 Bioblast Pharma Ltd.
  - 4.16.1 Bioblast Pharma Ltd. Company Information
  - 4.16.2 Bioblast Pharma Ltd. Business Overview
  - 4.16.3 Bioblast Pharma Ltd. Spinal Muscular Atrophy Medicine Sales, Revenue and Gross Margin (2021-2026)
  - 4.16.4 Bioblast Pharma Ltd. Spinal Muscular Atrophy Medicine Product Portfolio
  - 4.16.5 Bioblast Pharma Ltd. Recent Developments
- 4.17 AveXis, Inc.
  - 4.17.1 AveXis, Inc. Company Information
  - 4.17.2 AveXis, Inc. Business Overview
  - 4.17.3 AveXis, Inc. Spinal Muscular Atrophy Medicine Sales, Revenue and Gross Margin (2021-2026)

4.17.4 AveXis, Inc. Spinal Muscular Atrophy Medicine Product Portfolio

4.17.5 AveXis, Inc. Recent Developments

---

## 5 Global Spinal Muscular Atrophy Medicine Market Scenario by Region

5.1 Global Spinal Muscular Atrophy Medicine Market Size by Region: 2021 VS 2025 VS 2032

5.2 Global Spinal Muscular Atrophy Medicine Sales by Region: 2021-2032

5.2.1 Global Spinal Muscular Atrophy Medicine Sales by Region: 2021-2026

5.2.2 Global Spinal Muscular Atrophy Medicine Sales by Region: 2027-2032

5.3 Global Spinal Muscular Atrophy Medicine Revenue by Region: 2021-2032

5.3.1 Global Spinal Muscular Atrophy Medicine Revenue by Region: 2021-2026

5.3.2 Global Spinal Muscular Atrophy Medicine Revenue by Region: 2027-2032

5.4 North America Spinal Muscular Atrophy Medicine Market Facts & Figures by Country

5.4.1 North America Spinal Muscular Atrophy Medicine Market Size by Country: 2021 VS 2025 VS 2032

5.4.2 North America Spinal Muscular Atrophy Medicine Sales by Country (2021-2032)

5.4.3 North America Spinal Muscular Atrophy Medicine Revenue by Country (2021-2032)

5.4.4 United States

5.4.5 Canada

5.5 Europe Spinal Muscular Atrophy Medicine Market Facts & Figures by Country

5.5.1 Europe Spinal Muscular Atrophy Medicine Market Size by Country: 2021 VS 2025 VS 2032

5.5.2 Europe Spinal Muscular Atrophy Medicine Sales by Country (2021-2032)

5.5.3 Europe Spinal Muscular Atrophy Medicine Revenue by Country (2021-2032)

5.5.4 Germany

5.5.5 France

5.5.6 U.K.

5.5.7 Italy

5.5.8 Russia

5.5.9 Spain

5.5.10 Netherlands

5.5.11 Switzerland

5.5.12 Sweden

5.5.13 Poland

5.6 Asia Pacific Spinal Muscular Atrophy Medicine Market Facts & Figures by Country

5.6.1 Asia Pacific Spinal Muscular Atrophy Medicine Market Size by Country: 2021 VS 2025 VS 2032

5.6.2 Asia Pacific Spinal Muscular Atrophy Medicine Sales by Country (2021-2032)

5.6.3 Asia Pacific Spinal Muscular Atrophy Medicine Revenue by Country (2021-2032)

5.6.4 China

5.6.5 Japan

5.6.6 South Korea

5.6.7 India

5.6.8 Australia

5.6.9 Taiwan

5.6.10 Southeast Asia

5.7 South America Spinal Muscular Atrophy Medicine Market Facts & Figures by Country

5.7.1 South America Spinal Muscular Atrophy Medicine Market Size by Country: 2021 VS 2025 VS 2032

5.7.2 South America Spinal Muscular Atrophy Medicine Sales by Country (2021-2032)

5.7.3 South America Spinal Muscular Atrophy Medicine Revenue by Country (2021-2032)

5.7.4 Brazil

5.7.5 Argentina

5.7.6 Chile

## 5.8 Middle East and Africa Spinal Muscular Atrophy Medicine Market Facts & Figures by Country

5.8.1 Middle East and Africa Spinal Muscular Atrophy Medicine Market Size by Country: 2021 VS 2025 VS 2032

5.8.2 Middle East and Africa Spinal Muscular Atrophy Medicine Sales by Country (2021-2032)

5.8.3 Middle East and Africa Spinal Muscular Atrophy Medicine Revenue by Country (2021-2032)

5.8.4 Egypt

5.8.5 South Africa

5.8.6 Israel

5.8.7 Türkiye

5.8.8 GCC Countries

---

## 6 Segment by Type

6.1 Global Spinal Muscular Atrophy Medicine Sales by Type (2021-2032)

6.1.1 Global Spinal Muscular Atrophy Medicine Sales by Type (2021-2032) & (W Units)

6.1.2 Global Spinal Muscular Atrophy Medicine Sales Market Share by Type (2021-2032)

6.2 Global Spinal Muscular Atrophy Medicine Revenue by Type (2021-2032)

6.2.1 Global Spinal Muscular Atrophy Medicine Sales by Type (2021-2032) & (US\$ Million)

6.2.2 Global Spinal Muscular Atrophy Medicine Revenue Market Share by Type (2021-2032)

6.3 Global Spinal Muscular Atrophy Medicine Price by Type (2021-2032)

---

## 7 Segment by Application

7.1 Global Spinal Muscular Atrophy Medicine Sales by Application (2021-2032)

7.1.1 Global Spinal Muscular Atrophy Medicine Sales by Application (2021-2032) & (W Units)

7.1.2 Global Spinal Muscular Atrophy Medicine Sales Market Share by Application (2021-2032)

7.2 Global Spinal Muscular Atrophy Medicine Revenue by Application (2021-2032)

7.2.1 Global Spinal Muscular Atrophy Medicine Sales by Application (2021-2032) & (US\$ Million)

7.2.2 Global Spinal Muscular Atrophy Medicine Revenue Market Share by Application (2021-2032)

7.3 Global Spinal Muscular Atrophy Medicine Price by Application (2021-2032)

---

## 8 Value Chain and Sales Channels Analysis of the Market

8.1 Spinal Muscular Atrophy Medicine Value Chain Analysis

8.1.1 Spinal Muscular Atrophy Medicine Key Raw Materials

8.1.2 Raw Materials Key Suppliers

8.1.3 Spinal Muscular Atrophy Medicine Production Mode & Process

8.2 Spinal Muscular Atrophy Medicine Sales Channels Analysis

8.2.1 Direct Comparison with Distribution Share

8.2.2 Spinal Muscular Atrophy Medicine Distributors

8.2.3 Spinal Muscular Atrophy Medicine Customers

---

## 9 Global Spinal Muscular Atrophy Medicine Analyzing Market Dynamics

9.1 Spinal Muscular Atrophy Medicine Industry Trends

9.2 Spinal Muscular Atrophy Medicine Industry Drivers

9.3 Spinal Muscular Atrophy Medicine Industry Opportunities and Challenges

9.4 Spinal Muscular Atrophy Medicine Industry Restraints

---

## 10 Report Conclusion

## 11 Disclaimer

# List of Tables and Figures

---

## List of Tables:

- Table 1: Secondary Sources
- Table 2: Primary Sources
- Table 3: Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US\$ Million)
- Table 4: Market Value Comparison by Application (2021 VS 2025 VS 2032) & (US\$ Million)
- Table 5: Global Spinal Muscular Atrophy Medicine Volume and Revenue Market Size and CAGR of Manufacturers (2021 Versus 2025)
- Table 6: Global Spinal Muscular Atrophy Medicine Sales (W Units) of Manufacturers (2021-2026)
- Table 7: Global Spinal Muscular Atrophy Medicine Sales Market Share by Manufacturers (2021-2026)
- Table 8: Global Spinal Muscular Atrophy Medicine Revenue of Manufacturers (2021-2026)
- Table 9: Global Spinal Muscular Atrophy Medicine Revenue Share by Manufacturers (2021-2026)
- Table 10: Global Market Spinal Muscular Atrophy Medicine Average Price (US\$/Unit) of Manufacturers (2021-2026)
- Table 11: Global Spinal Muscular Atrophy Medicine Industry Ranking, 2024 VS 2025 VS 2026
- Table 12: Global Manufacturers of Spinal Muscular Atrophy Medicine, Manufacturing Sites & Headquarters
- Table 13: Global Manufacturers of Spinal Muscular Atrophy Medicine, Product Type & Application
- Table 14: Global Spinal Muscular Atrophy Medicine Manufacturers Established Date
- Table 15: Global Manufacturers Market Concentration Ratio (CR5 and HHI)
- Table 16: Global Spinal Muscular Atrophy Medicine by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025)
- Table 17: Manufacturers Mergers & Acquisitions, Expansion Plans)
- Table 18: Novartis AG Company Information
- Table 19: Novartis AG Business Overview
- Table 20: Novartis AG Spinal Muscular Atrophy Medicine Sales (W Units), Revenue (US\$ Million), Price (US\$/Unit) and Gross Margin (2021-2026)
- Table 21: Novartis AG Spinal Muscular Atrophy Medicine Product Portfolio
- Table 22: Novartis AG Recent Developments
- Table 23: Astellas Pharma Inc. Company Information
- Table 24: Astellas Pharma Inc. Business Overview
- Table 25: Astellas Pharma Inc. Spinal Muscular Atrophy Medicine Sales (W Units), Revenue (US\$ Million), Price (US\$/Unit) and Gross Margin (2021-2026)
- Table 26: Astellas Pharma Inc. Spinal Muscular Atrophy Medicine Product Portfolio
- Table 27: Astellas Pharma Inc. Recent Developments
- Table 28: WAVE Life Sciences Ltd. Company Information
- Table 29: WAVE Life Sciences Ltd. Business Overview
- Table 30: WAVE Life Sciences Ltd. Spinal Muscular Atrophy Medicine Sales (W Units), Revenue (US\$ Million), Price (US\$/Unit) and Gross Margin (2021-2026)
- Table 31: WAVE Life Sciences Ltd. Spinal Muscular Atrophy Medicine Product Portfolio
- Table 32: WAVE Life Sciences Ltd. Recent Developments
- Table 33: Vybion, Inc. Company Information
- Table 34: Vybion, Inc. Business Overview
- Table 35: Vybion, Inc. Spinal Muscular Atrophy Medicine Sales (W Units), Revenue (US\$ Million), Price (US\$/Unit) and Gross Margin (2021-2026)
- Table 36: Vybion, Inc. Spinal Muscular Atrophy Medicine Product Portfolio
- Table 37: Vybion, Inc. Recent Developments
- Table 38: Voyager Therapeutics, Inc. Company Information
- Table 39: Voyager Therapeutics, Inc. Business Overview
- Table 40: Voyager Therapeutics, Inc. Spinal Muscular Atrophy Medicine Sales (W Units), Revenue (US\$ Million), Price (US\$/Unit) and Gross Margin (2021-2026)
- Table 41: Voyager Therapeutics, Inc. Spinal Muscular Atrophy Medicine Product Portfolio
- Table 42: Voyager Therapeutics, Inc. Recent Developments
- Table 43: Sarepta Therapeutics, Inc. Company Information
- Table 44: Sarepta Therapeutics, Inc. Business Overview
- Table 45: Sarepta Therapeutics, Inc. Spinal Muscular Atrophy Medicine Sales (W Units), Revenue (US\$ Million), Price (US\$/Unit) and Gross Margin (2021-2026)
- Table 46: Sarepta Therapeutics, Inc. Spinal Muscular Atrophy Medicine Product Portfolio
- Table 47: Sarepta Therapeutics, Inc. Recent Developments

- Table 48: Neurotune AG Company Information
- Table 49: Neurotune AG Business Overview
- Table 50: Neurotune AG Spinal Muscular Atrophy Medicine Sales (W Units), Revenue (US\$ Million), Price (US\$/Unit) and Gross Margin (2021-2026)
- Table 51: Neurotune AG Spinal Muscular Atrophy Medicine Product Portfolio
- Table 52: Neurotune AG Recent Developments
- Table 53: Neurodyn Inc. Company Information
- Table 54: Neurodyn Inc. Business Overview
- Table 55: Neurodyn Inc. Spinal Muscular Atrophy Medicine Sales (W Units), Revenue (US\$ Million), Price (US\$/Unit) and Gross Margin (2021-2026)
- Table 56: Neurodyn Inc. Spinal Muscular Atrophy Medicine Product Portfolio
- Table 57: Neurodyn Inc. Recent Developments
- Table 58: Longevity Biotech, Inc Company Information
- Table 59: Longevity Biotech, Inc Business Overview
- Table 60: Longevity Biotech, Inc Spinal Muscular Atrophy Medicine Sales (W Units), Revenue (US\$ Million), Price (US\$/Unit) and Gross Margin (2021-2026)
- Table 61: Longevity Biotech, Inc Spinal Muscular Atrophy Medicine Product Portfolio
- Table 62: Longevity Biotech, Inc Recent Developments
- Table 63: Ionis Pharmaceuticals, Inc. Company Information
- Table 64: Ionis Pharmaceuticals, Inc. Business Overview
- Table 65: Ionis Pharmaceuticals, Inc. Spinal Muscular Atrophy Medicine Sales (W Units), Revenue (US\$ Million), Price (US\$/Unit) and Gross Margin (2021-2026)
- Table 66: Ionis Pharmaceuticals, Inc. Spinal Muscular Atrophy Medicine Product Portfolio
- Table 67: Ionis Pharmaceuticals, Inc. Recent Developments
- Table 68: GMP-Orphan SAS Company Information
- Table 69: GMP-Orphan SAS Business Overview
- Table 70: GMP-Orphan SAS Spinal Muscular Atrophy Medicine Sales (W Units), Revenue (US\$ Million), Price (US\$/Unit) and Gross Margin (2021-2026)
- Table 71: GMP-Orphan SAS Spinal Muscular Atrophy Medicine Product Portfolio
- Table 72: GMP-Orphan SAS Recent Developments
- Table 73: Genzyme Corporation Company Information
- Table 74: Genzyme Corporation Business Overview
- Table 75: Genzyme Corporation Spinal Muscular Atrophy Medicine Sales (W Units), Revenue (US\$ Million), Price (US\$/Unit) and Gross Margin (2021-2026)
- Table 76: Genzyme Corporation Spinal Muscular Atrophy Medicine Product Portfolio
- Table 77: Genzyme Corporation Recent Developments
- Table 78: Genethon Company Information
- Table 79: Genethon Business Overview
- Table 80: Genethon Spinal Muscular Atrophy Medicine Sales (W Units), Revenue (US\$ Million), Price (US\$/Unit) and Gross Margin (2021-2026)
- Table 81: Genethon Spinal Muscular Atrophy Medicine Product Portfolio
- Table 82: Genethon Recent Developments
- Table 83: F. Hoffmann-La Roche Ltd. Company Information
- Table 84: F. Hoffmann-La Roche Ltd. Business Overview
- Table 85: F. Hoffmann-La Roche Ltd. Spinal Muscular Atrophy Medicine Sales (W Units), Revenue (US\$ Million), Price (US\$/Unit) and Gross Margin (2021-2026)
- Table 86: F. Hoffmann-La Roche Ltd. Spinal Muscular Atrophy Medicine Product Portfolio
- Table 87: F. Hoffmann-La Roche Ltd. Recent Developments
- Table 88: Cytokinetics, Inc. 24 Company Information
- Table 89: Cytokinetics, Inc. 24 Business Overview
- Table 90: Cytokinetics, Inc. 24 Spinal Muscular Atrophy Medicine Sales (W Units), Revenue (US\$ Million), Price (US\$/Unit) and Gross Margin (2021-2026)
- Table 91: Cytokinetics, Inc. 24 Spinal Muscular Atrophy Medicine Product Portfolio
- Table 92: Cytokinetics, Inc. 24 Recent Developments
- Table 93: Bioblast Pharma Ltd. Company Information
- Table 94: Bioblast Pharma Ltd. Business Overview
- Table 95: Bioblast Pharma Ltd. Spinal Muscular Atrophy Medicine Sales (W Units), Revenue (US\$ Million), Price (US\$/Unit) and Gross Margin (2021-2026)
- Table 96: Bioblast Pharma Ltd. Spinal Muscular Atrophy Medicine Product Portfolio
- Table 97: Bioblast Pharma Ltd. Recent Developments
- Table 98: AveXis, Inc. Company Information
- Table 99: AveXis, Inc. Business Overview
- Table 100: AveXis, Inc. Spinal Muscular Atrophy Medicine Sales (W Units), Revenue (US\$ Million), Price (US\$/Unit) and Gross Margin (2021-2026)
- Table 101: AveXis, Inc. Spinal Muscular Atrophy Medicine Product Portfolio

- Table 102: AveXis, Inc. Recent Developments
- Table 103: Global Spinal Muscular Atrophy Medicine Market Size by Region (US\$ Million): 2021 VS 2025 VS 2032
- Table 104: Global Spinal Muscular Atrophy Medicine Sales by Region (2021-2026) & (W Units)
- Table 105: Global Spinal Muscular Atrophy Medicine Sales Market Share by Region (2021-2026)
- Table 106: Global Spinal Muscular Atrophy Medicine Sales by Region (2027-2032) & (W Units)
- Table 107: Global Spinal Muscular Atrophy Medicine Sales Market Share by Region (2027-2032)
- Table 108: Global Spinal Muscular Atrophy Medicine Revenue by Region (2021-2026) & (US\$ Million)
- Table 109: Global Spinal Muscular Atrophy Medicine Revenue Market Share by Region (2021-2026)
- Table 110: Global Spinal Muscular Atrophy Medicine Revenue by Region (2027-2032) & (US\$ Million)
- Table 111: Global Spinal Muscular Atrophy Medicine Revenue Market Share by Region (2027-2032)
- Table 112: North America Spinal Muscular Atrophy Medicine Revenue by Country: 2021 VS 2025 VS 2032 (US\$ Million)
- Table 113: North America Spinal Muscular Atrophy Medicine Sales by Country (2021-2026) & (W Units)
- Table 114: North America Spinal Muscular Atrophy Medicine Sales by Country (2027-2032) & (W Units)
- Table 115: North America Spinal Muscular Atrophy Medicine Revenue by Country (2021-2026) & (US\$ Million)
- Table 116: North America Spinal Muscular Atrophy Medicine Revenue by Country (2027-2032) & (US\$ Million)
- Table 117: Europe Spinal Muscular Atrophy Medicine Revenue by Country: 2021 VS 2025 VS 2032 (US\$ Million)
- Table 118: Europe Spinal Muscular Atrophy Medicine Sales by Country (2021-2026) & (W Units)
- Table 119: Europe Spinal Muscular Atrophy Medicine Sales by Country (2027-2032) & (W Units)
- Table 120: Europe Spinal Muscular Atrophy Medicine Revenue by Country (2021-2026) & (US\$ Million)
- Table 121: Europe Spinal Muscular Atrophy Medicine Revenue by Country (2027-2032) & (US\$ Million)
- Table 122: Asia Pacific Spinal Muscular Atrophy Medicine Revenue by Country: 2021 VS 2025 VS 2032 (US\$ Million)
- Table 123: Asia Pacific Spinal Muscular Atrophy Medicine Sales by Country (2021-2026) & (W Units)
- Table 124: Asia Pacific Spinal Muscular Atrophy Medicine Sales by Country (2027-2032) & (W Units)
- Table 125: Asia Pacific Spinal Muscular Atrophy Medicine Revenue by Country (2021-2026) & (US\$ Million)
- Table 126: Asia Pacific Spinal Muscular Atrophy Medicine Revenue by Country (2027-2032) & (US\$ Million)
- Table 127: South America Spinal Muscular Atrophy Medicine Revenue by Country: 2021 VS 2025 VS 2032 (US\$ Million)
- Table 128: South America Spinal Muscular Atrophy Medicine Sales by Country (2021-2026) & (W Units)
- Table 129: South America Spinal Muscular Atrophy Medicine Sales by Country (2027-2032) & (W Units)
- Table 130: South America Spinal Muscular Atrophy Medicine Revenue by Country (2021-2026) & (US\$ Million)
- Table 131: South America Spinal Muscular Atrophy Medicine Revenue by Country (2027-2032) & (US\$ Million)
- Table 132: Middle East and Africa Spinal Muscular Atrophy Medicine Revenue by Country: 2021 VS 2025 VS 2032 (US\$ Million)
- Table 133: Middle East and Africa Spinal Muscular Atrophy Medicine Sales by Country (2021-2026) & (W Units)
- Table 134: Middle East and Africa Spinal Muscular Atrophy Medicine Sales by Country (2027-2032) & (W Units)
- Table 135: Middle East and Africa Spinal Muscular Atrophy Medicine Revenue by Country (2021-2026) & (US\$ Million)
- Table 136: Middle East and Africa Spinal Muscular Atrophy Medicine Revenue by Country (2027-2032) & (US\$ Million)
- Table 137: Global Spinal Muscular Atrophy Medicine Sales by Type (2021-2026) & (W Units)
- Table 138: Global Spinal Muscular Atrophy Medicine Sales by Type (2027-2032) & (W Units)
- Table 139: Global Spinal Muscular Atrophy Medicine Sales Market Share by Type (2021-2026)
- Table 140: Global Spinal Muscular Atrophy Medicine Sales Market Share by Type (2027-2032)
- Table 141: Global Spinal Muscular Atrophy Medicine Revenue by Type (2021-2026) & (US\$ Million)
- Table 142: Global Spinal Muscular Atrophy Medicine Revenue by Type (2027-2032) & (US\$ Million)
- Table 143: Global Spinal Muscular Atrophy Medicine Revenue Market Share by Type (2021-2026)
- Table 144: Global Spinal Muscular Atrophy Medicine Revenue Market Share by Type (2027-2032)
- Table 145: Global Spinal Muscular Atrophy Medicine Price by Type (2021-2026) & (US\$/Unit)
- Table 146: Global Spinal Muscular Atrophy Medicine Price by Type (2027-2032) & (US\$/Unit)
- Table 147: Global Spinal Muscular Atrophy Medicine Sales by Application (2021-2026) & (W Units)
- Table 148: Global Spinal Muscular Atrophy Medicine Sales by Application (2027-2032) & (W Units)
- Table 149: Global Spinal Muscular Atrophy Medicine Sales Market Share by Application (2021-2026)
- Table 150: Global Spinal Muscular Atrophy Medicine Sales Market Share by Application (2027-2032)
- Table 151: Global Spinal Muscular Atrophy Medicine Revenue by Application (2021-2026) & (US\$ Million)
- Table 152: Global Spinal Muscular Atrophy Medicine Revenue by Application (2027-2032) & (US\$ Million)
- Table 153: Global Spinal Muscular Atrophy Medicine Revenue Market Share by Application (2021-2026)
- Table 154: Global Spinal Muscular Atrophy Medicine Revenue Market Share by Application (2027-2032)
- Table 155: Global Spinal Muscular Atrophy Medicine Price by Application (2021-2026) & (US\$/Unit)
- Table 156: Global Spinal Muscular Atrophy Medicine Price by Application (2027-2032) & (US\$/Unit)
- Table 157: Key Raw Materials
- Table 158: Raw Materials Key Suppliers
- Table 159: Spinal Muscular Atrophy Medicine Distributors List
- Table 160: Spinal Muscular Atrophy Medicine Customers List
- Table 161: Spinal Muscular Atrophy Medicine Industry Trends
- Table 162: Spinal Muscular Atrophy Medicine Industry Drivers
- Table 163: Spinal Muscular Atrophy Medicine Industry Restraints
- Table 164: Authors List of This Report

## List of Figures:

- Figure 1: Research Methodology
- Figure 2: Research Process
- Figure 3: Key Executives Interviewed
- Figure 4: Spinal Muscular Atrophy Medicine Product Image
- Figure 5: Global Spinal Muscular Atrophy Medicine Revenue (US\$ Million), 2021 VS 2025 VS 2032
- Figure 6: Global Spinal Muscular Atrophy Medicine Market Size (2021-2032) & (US\$ Million)
- Figure 7: Global Spinal Muscular Atrophy Medicine Sales (2021-2032) & (W Units)
- Figure 8: Global Spinal Muscular Atrophy Medicine Average Price (US\$/Unit) & (2021-2032)
- Figure 9: LMI-070 Product Image
- Figure 10: ND-602 Product Image
- Figure 11: NT-1654 Product Image
- Figure 12: NXD-30001 Product Image
- Figure 13: Nusinersen Product Image
- Figure 14: Others Product Image
- Figure 15: Hospital Product Image
- Figure 16: Clinic Product Image
- Figure 17: Others Product Image
- Figure 18: Global Spinal Muscular Atrophy Medicine Revenue Share by Manufacturers in 2025
- Figure 19: Global Manufacturers of Spinal Muscular Atrophy Medicine, Manufacturing Sites & Headquarters
- Figure 20: Global Top 5 and 10 Spinal Muscular Atrophy Medicine Players Market Share by Revenue in 2025
- Figure 21: Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025
- Figure 22: Global Spinal Muscular Atrophy Medicine Market Size by Region (US\$ Million): 2021 VS 2025 VS 2032
- Figure 23: Global Spinal Muscular Atrophy Medicine Sales by Region in 2025
- Figure 24: Global Spinal Muscular Atrophy Medicine Revenue by Region in 2025
- Figure 25: North America Spinal Muscular Atrophy Medicine Market Size by Country in 2025
- Figure 26: North America Spinal Muscular Atrophy Medicine Sales Market Share by Country (2021-2032)
- Figure 27: North America Spinal Muscular Atrophy Medicine Revenue Market Share by Country (2021-2032)
- Figure 28: United States Spinal Muscular Atrophy Medicine Revenue Growth Rate (2021-2032) & (US\$ Million)
- Figure 29: Canada Spinal Muscular Atrophy Medicine Revenue Growth Rate (2021-2032) & (US\$ Million)
- Figure 30: Europe Spinal Muscular Atrophy Medicine Market Size by Country in 2025
- Figure 31: Europe Spinal Muscular Atrophy Medicine Sales Market Share by Country (2021-2032)
- Figure 32: Europe Spinal Muscular Atrophy Medicine Revenue Market Share by Country (2021-2032)
- Figure 33: Germany Spinal Muscular Atrophy Medicine Revenue Growth Rate (2021-2032) & (US\$ Million)
- Figure 34: France Spinal Muscular Atrophy Medicine Revenue Growth Rate (2021-2032) & (US\$ Million)
- Figure 35: U.K. Spinal Muscular Atrophy Medicine Revenue Growth Rate (2021-2032) & (US\$ Million)
- Figure 36: Italy Spinal Muscular Atrophy Medicine Revenue Growth Rate (2021-2032) & (US\$ Million)
- Figure 37: Russia Spinal Muscular Atrophy Medicine Revenue Growth Rate (2021-2032) & (US\$ Million)
- Figure 38: Spain Spinal Muscular Atrophy Medicine Revenue Growth Rate (2021-2032) & (US\$ Million)
- Figure 39: Netherlands Spinal Muscular Atrophy Medicine Revenue Growth Rate (2021-2032) & (US\$ Million)
- Figure 40: Switzerland Spinal Muscular Atrophy Medicine Revenue Growth Rate (2021-2032) & (US\$ Million)
- Figure 41: Sweden Spinal Muscular Atrophy Medicine Revenue Growth Rate (2021-2032) & (US\$ Million)
- Figure 42: Poland Spinal Muscular Atrophy Medicine Revenue Growth Rate (2021-2032) & (US\$ Million)
- Figure 43: Asia Pacific Spinal Muscular Atrophy Medicine Market Size by Country in 2025
- Figure 44: Asia Pacific Spinal Muscular Atrophy Medicine Sales Market Share by Country (2021-2032)
- Figure 45: Asia Pacific Spinal Muscular Atrophy Medicine Revenue Market Share by Country (2021-2032)
- Figure 46: China Spinal Muscular Atrophy Medicine Revenue Growth Rate (2021-2032) & (US\$ Million)
- Figure 47: Japan Spinal Muscular Atrophy Medicine Revenue Growth Rate (2021-2032) & (US\$ Million)
- Figure 48: South Korea Spinal Muscular Atrophy Medicine Revenue Growth Rate (2021-2032) & (US\$ Million)
- Figure 49: India Spinal Muscular Atrophy Medicine Revenue Growth Rate (2021-2032) & (US\$ Million)
- Figure 50: Australia Spinal Muscular Atrophy Medicine Revenue Growth Rate (2021-2032) & (US\$ Million)
- Figure 51: Taiwan Spinal Muscular Atrophy Medicine Revenue Growth Rate (2021-2032) & (US\$ Million)
- Figure 52: Southeast Asia Spinal Muscular Atrophy Medicine Revenue Growth Rate (2021-2032) & (US\$ Million)
- Figure 53: Southeast Asia Spinal Muscular Atrophy Medicine Revenue Growth Rate (2021-2032) & (US\$ Million)
- Figure 54: South America Spinal Muscular Atrophy Medicine Market Size by Country in 2025
- Figure 55: South America Spinal Muscular Atrophy Medicine Sales Market Share by Country (2021-2032)
- Figure 56: South America Spinal Muscular Atrophy Medicine Revenue Market Share by Country (2021-2032)
- Figure 57: Brazil Spinal Muscular Atrophy Medicine Revenue Growth Rate (2021-2032) & (US\$ Million)
- Figure 58: Argentina Spinal Muscular Atrophy Medicine Revenue Growth Rate (2021-2032) & (US\$ Million)
- Figure 59: Chile Spinal Muscular Atrophy Medicine Revenue Growth Rate (2021-2032) & (US\$ Million)
- Figure 60: Middle East and Africa Spinal Muscular Atrophy Medicine Market Size by Country in 2025
- Figure 61: Middle East and Africa Spinal Muscular Atrophy Medicine Sales Market Share by Country (2021-2032)
- Figure 62: Middle East and Africa Spinal Muscular Atrophy Medicine Revenue Market Share by Country (2021-2032)

- Figure 63: Egypt Spinal Muscular Atrophy Medicine Revenue Growth Rate (2021-2032) & (US\$ Million)
- Figure 64: South Africa Spinal Muscular Atrophy Medicine Revenue Growth Rate (2021-2032) & (US\$ Million)
- Figure 65: Israel Spinal Muscular Atrophy Medicine Revenue Growth Rate (2021-2032) & (US\$ Million)
- Figure 66: Türkiye Spinal Muscular Atrophy Medicine Revenue Growth Rate (2021-2032) & (US\$ Million)
- Figure 67: GCC Countries Spinal Muscular Atrophy Medicine Revenue Growth Rate (2021-2032) & (US\$ Million)
- Figure 68: Global Spinal Muscular Atrophy Medicine Sales Market Share by Type (2021-2032)
- Figure 69: Global Spinal Muscular Atrophy Medicine Revenue Market Share by Type (2021-2032)
- Figure 70: Global Spinal Muscular Atrophy Medicine Price (US\$/Unit) by Type (2021-2032)
- Figure 71: Global Spinal Muscular Atrophy Medicine Sales Market Share by Application (2021-2032)
- Figure 72: Global Spinal Muscular Atrophy Medicine Revenue Market Share by Application (2021-2032)
- Figure 73: Global Spinal Muscular Atrophy Medicine Price (US\$/Unit) by Application (2021-2032)
- Figure 74: Spinal Muscular Atrophy Medicine Value Chain
- Figure 75: Spinal Muscular Atrophy Medicine Production Mode & Process
- Figure 76: Direct Comparison with Distribution Share
- Figure 77: Distributors Profiles
- Figure 78: Spinal Muscular Atrophy Medicine Industry Opportunities and Challenges